Mortality due to amyotrophic lateral sclerosis and Parkinson's disease among melanoma patients

Neuroepidemiology

Volumn 28, Issue 1, 2007, Pages 16-20

  Baade, P D ^a   Fritschi, L ^a,b   Freedman, D M ^c  

^a VIERTEL CENTRE FOR RESEARCH IN CANCER CONTROL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Amyotrophic lateral sclerosis, mortality; Melanoma; Parkinson's disease, mortality

Indexed keywords

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; AUSTRALIA; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; MORTALITY; PARKINSON DISEASE; POPULATION; STANDARDIZATION; SURVIVAL TIME; SURVIVOR; UNITED STATES;

AMYOTROPHIC LATERAL SCLEROSIS; AUSTRALIA; COHORT STUDIES; FEMALE; HUMANS; MALE; MELANOMA; PARKINSON DISEASE; RISK ASSESSMENT; SKIN NEOPLASMS; TIME FACTORS;

EID: 33846864663     PISSN: 02515350     EISSN: None     Source Type: Journal    
DOI: 10.1159/000097851     Document Type: Article

References (32)

1. Brown RH: Amyotrophic lateral sclerosis - a new role for old drugs. N Engl J Med 2005;352:1376-1378.
2. Rowland LP, Shneider NA: Amyotrophic lateral sclerosis. N Engl J Med 2001;344:1688-1700.
3. Sejvar JJ, Holman RC, Bresee JS, Kochanek KD, Schonberger LB: Amyotrophic lateral sclerosis mortality in the United States, 1979-2001. Neuroepidemiology 2005;25:144-152.
4. National Institute of Neurological Disorders and Stroke, National Institutes of Health: Parkinson's disease: hope through research. 2006. http://www.ninds.nih.gov/disorders/parkinsons_disease/detail_parkinsons_disease. htm (accessed 5th April 2006).
5. Fiala KH, Whetteckey J, Manyam BV: Malignant melanoma and levodopa in Parkinson's disease: causality or coincidence? Parkinsonism Relat Disord 2003;9:321-327.
6. Olsen JH, Friis S, Frederiksen K, McLaughlin JK, Mellemkjaer L, Moller H: Atypical cancer pattern in patients with Parkinson's disease. Br J Cancer 2005;92:201-205.
7. Freedman DM, Travis LB, Gridley G, Kuncl RW: Amyotrophic lateral sclerosis mortality in 1.9 million US cancer survivors. Neuroepidemiology 2005;25:176-180.
8. Baade PD, Fritschi L, Eakin EG: Non-cancer mortality among people diagnosed with cancer. Cancer Causes Control 2006;17:287-297.
9. Leone M, Chandra V, Schoenberg BS: Motor neuron disease in the United States, 1971 and 1973-1978: patterns of mortality and associated conditions at the time of death. Neurology 1987;37:1339-1343.
10. ABS: Causes of death 2003 (appendix: Comparability of data over time). Catalogue No. 3303.0. Canberra, Australian Bureau of Statistics, 2005. www.abs.gov.au.
11. Griffiths C, Rooney C: Trends in mortality from Alzheimer's disease, Parkinson's disease and dementia, England and Wales, 1979-2004. Health Stat Q 2006:6-14.
12. SAS Institute Inc: SAS OnlineDoc®, Version 9.1.2. Cary, SAS Institute Inc, 2004.
13. Coory M, Baade PD, Aitken JF, Smithers M, McLeod GRC, Ring I: Trends for in situ and invasive melanoma in Queensland, Australia, 1982 to 2002. Cancer Causes Control 2006;17:21-27.
14. NHMRC: Clinical Practice Guidelines. The Management of Cutaneous Melanoma. Canberra, Australian Cancer Network, National Health and Medical Research Council, 1999.
15. Del Aguila MA, Longstreth WT Jr, McGuire V, Koepsell TD, van Belle G: Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology 2003;60:813-819.
16. De Rijk M, Breteler M, Graveland G, Ott A, Grobbee D, van der Meche F, Hofman A: Prevalence of Parkinson's disease in the elderly: the Rotterdam Study. Neurology 1995;45:2143-2146.
17. Roman GC: Neuroepidemiology of amyotrophic lateral sclerosis: clues to aetiology and pathogenesis. J Neurol Neurosurg Psychiatry 1996;61:131-137.
18. Chio A, Magnani C, Oddenino E, Tolardo G, Schiffer D: Accuracy of death certificate diagnosis of amyotrophic lateral sclerosis. J Epidemiol Community Health 1992;46:517-518.
19. Ragonese P, Salemi G, Aridon P, Conte S, Cuccia G, Lupo I, Savettieri G: Accuracy of death certificates for motor neuron disease and multiple sclerosis in the province of Palermo in southern Italy. Neuroepidemiology 2002;21:148-152.
20. Phillips NJ, Reay J, Martyn CN: Validity of mortality data for Parkinson's disease. J Epidemiol Community Health 1999;53:587-588.
21. Eisen A, Calne D: Amyotrophic lateral sclerosis, Parkinson's disease and Alzheimer's disease: phylogenetic disorders of the human neocortex sharing many characteristics. Can J Neurol Sci 1992;19:117-123.
22. Lanska DJ: The geographic distribution of Parkinson's disease mortality in the United States. J Neurol Sci 1997;150:63-70.
23. Siple JF, Schneider DC, Wanlass WA, Rosenblatt BK: Levodopa therapy and the risk of malignant melanoma. Ann Pharmacother 2000;34:382-385.
24. Weiner WJ, Singer C, Sanchez-Ramos JR, Goldenberg JN: Levodopa, melanoma, and Parkinson's disease. Neurology 1993;43:674-677.
25. Pawlik TM, Sondak VK: Malignant melanoma: current state of primary and adjuvant treatment. Crit Rev Oncol Hematol 2003;45:245-264.
26. NHMRC: Clinical Practice Guidelines for the Management of Cutaneous Melanoma. Canberra, National Health and Medical Research Council, 1999. http://www.nhmrc.gov.au/publications/synopses/cp68syn.htm.
27. Coory M, Smithers M, Aitken J, Baade P, Ring I: Urban-rural differences in survival from cutaneous melanoma in Queensland. Aust NZ J Public Health 2006;30:71-74.
28. Majoor-Krakauer D, Ottman R, Johnson WG, Rowland LP: Familial aggregation of amyotrophic lateral sclerosis, dementia, and Parkinson's disease: evidence of shared genetic susceptibility. Neurology 1994;44:1872-1877.
29. Cruz DC, Nelson LM, McGuire V, Longstreth WT Jr: Physical trauma and family history of neurodegenerative diseases in amyotrophic lateral sclerosis: a population-based case-control study. Neuroepidemiology 1999;18:101-110.
30. Christiansen JH, Coles EG, Wilkinson DG: Molecular control of neural crest formation, migration and differentiation. Curr Opin Cell Biol 2000;12:719-724.
31. Sandyk R: Serotonergic mechanisms in amyotrophic lateral sclerosis. Int J Neurosci 2006;116:775-826.
32. Zanetti R, Loria D, Rosso S: Melanoma, Parkinson's disease and levodopa: causal or spurious link? A review of the literature. Melanoma Res 2006;16:201-206.